Intravitreal bevacizumab for choroidal neovascularization associated with angioid streaks: Long-term results

Autor: S Karthikeyan, Renuka Nikit Sarwate, Manasi Patel, T Lekha, Hari Narayan Prasad
Rok vydání: 2017
Předmět:
Male
Vascular Endothelial Growth Factor A
safety
medicine.medical_specialty
Visual acuity
genetic structures
Bevacizumab
Visual Acuity
Ocular hypertension
Angiogenesis Inhibitors
Physical examination
bevacizumab
choroidal neovascularization
Lesion
03 medical and health sciences
0302 clinical medicine
Recurrence
Ophthalmology
medicine
Humans
Fluorescein Angiography
Retrospective Studies
Angioid streaks
medicine.diagnostic_test
business.industry
Incidence (epidemiology)
General Medicine
Middle Aged
medicine.disease
eye diseases
Surgery
long-term efficacy
Treatment Outcome
Choroidal neovascularization
Intravitreal Injections
030221 ophthalmology & optometry
Female
Original Article
sense organs
medicine.symptom
business
Tomography
Optical Coherence
030217 neurology & neurosurgery
Follow-Up Studies
medicine.drug
Zdroj: Middle East African Journal of Ophthalmology
ISSN: 0974-9233
DOI: 10.4103/meajo.meajo_17_17
Popis: PURPOSE: The purpose of the study was to evaluate the long-term efficacy and safety of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularization (CNV) secondary to angioid streaks (AS). MATERIALS AND METHODS: Noncomparative, interventional retrospective case series involving ten patients (15 eyes) with a minimum follow-up of 25 months following IVB for AS-associated CNV. Demographic and clinical details at baseline and during follow-up were collected from patient records. Detailed clinical examination was followed by fundus fluorescein angiography and optical coherence tomography to confirm CNV. Both primary and recurrent CNVs were treated with monthly injections of IVB till the lesion stabilized. Primary outcome measures were the percentage of patients with stable or improved visual acuity (VA) and with stable or decreased central retinal thickness (CRT) at the last visit. Secondary outcome measure was the incidence of ocular and systemic complications. RESULTS: Recurrence was observed in 11 eyes (73.33%) over a mean follow-up of 57.33 months (range: 25–100). A mean number of injections administered was 5.60. VA improved or stabilized in 73.33% and deteriorated in 26.67% of eyes at the final visit. Mean CRT improved from 324.40 μm at baseline to 265.53 μm at final visit, which was statistically significant. Complications observed were ocular hypertension in one patient and thromboembolic event in another patient. CONCLUSIONS: IVB appears to be a safe and effective option to treat CNV and to preserve vision over a prolonged period. It cannot eliminate the risk of recurrent CNV indicating the need for more effective treatments to arrest this visually debilitating condition.
Databáze: OpenAIRE
Externí odkaz: